secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lexeo Therapeutics, Inc. (LXEO)
CIK:        0001907108
Form:       8-K
Filed at:   2025-04-07T23:59:59+00:00
Accession:  0000950170-25-051345
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexeo reports positive interim Phase 1/2 data for LX2006 in FA cardiomyopathy; 25% LVMI reduction
--------------------------------------------------------------------------------

- Participants with abnormal LVMI at baseline achieved 25% mean reduction by 12 months or sooner.
- High-dose cohort (Cohort 3) showed 115% mean increase in cardiac frataxin expression at 3 months.
- LX2006 well tolerated; no Grade 3+ SAEs, no complement activation, no discontinuations.
- FDA alignment on co-primary endpoints (LVMI >10% improvement, any frataxin increase) for registrational study.
- Registrational study expected to initiate by early 2026; natural history study enrollment starts Q2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1907108/000095017025051345/0000950170-25-051345-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1907108/000095017025051345/lxeo-20250407.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-051345

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer